AdTech Vendor · vs · AdTech Vendor
KNOREX vs NextRoll
Structured technology and market comparison · 2026
Direct Feature Comparison
KNOREX · vs · NextRollCross-channel DSP and advertising automation platform for enterprises and agencies.
Adtech platform for mid-market advertising and B2B account-based marketing.
Analyze all overlapping signals and tech stacks for KNOREX and NextRoll
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between KNOREX and NextRoll?
Knorex positions as an enterprise-grade cross-channel DSP focusing on automation across diverse media like CTV and audio for agencies. In contrast, NextRoll adopts a hybrid adtech-martech approach, primarily serving mid-market firms with a specialized focus on B2B account-based marketing and retargeting. While Knorex prioritizes operational efficiency in execution, NextRoll emphasizes audience identification and attribution within the B2B sales cycle.
How do the features of KNOREX and NextRoll compare?
Knorex provides deep programmatic consolidation, integrating social, search, and audio workflows into a single automation engine. NextRoll excels in account-level targeting and retargeting features, specifically optimized for B2B buyer journeys. While Knorex offers broader channel support for media efficiency, NextRoll delivers integrated attribution and account identification tools that bridge the gap between advertising spend and revenue-focused marketing outcomes.
What are the top alternatives to KNOREX and NextRoll?
When evaluating KNOREX and NextRoll, enterprise buyers also consider other platforms in Demand-Side Platform (DSP), In-App, and Native & Contextual Ads. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
Market Signals
Recent Market Signals & Activity: KNOREX vs NextRoll
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
KNOREX
Recent Signals
- ·https://martechseries.com/feed/M&A
KNOREX Plans Carve-Out of AscendX Publisher Business
KNOREX Ltd., a provider of AI-driven cross-channel programmatic advertising solutions, announced it is pursuing a strategic carve-out of its wholly-owned subsidiary AscendX Media Technologies Pte. Ltd., a publisher monetization platform. Under the proposed structure, AscendX would be independently capitalized with external investment, allowing KNOREX to retain a minority equity interest and eliminate the need to fund AscendX's future growth. Since its formation in June 2025, AscendX has moved into commercial deployment with 10 live publishers, over 2 billion ad impressions in 2026, and integrations with major demand platforms such as The Trade Desk, Meta Audience Network, Microsoft Monetize, OpenX, and Magnite. The carve-out is subject to negotiation and approvals. CEO Phu Le of AscendX will have the transaction reviewed by KNOREX's Audit Committee due to his dual role.
- KNOREX Ltd. is pursuing a strategic carve-out of AscendX Media Technologies Pte. Ltd., its wholly-owned publisher monetization subsidiary.
- AscendX has attracted interest from external investors and is expected to be independently capitalized.
- Since formation in June 2025, AscendX has deployed across 10 live publishers and supports over 2.0 billion ad impressions year-to-date 2026.
- ·SEC APIfinancials
20-F Financial Filing Analysis for KNOREX (2026-08-19)
KNOREX LTD. filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, reporting total revenue of approximately $6.04 million, representing a 44% year-over-year decline compared to $10.81 million in FY2024. The contraction was primarily driven by a substantial spending reduction from its largest customer (whose revenue contribution fell from 73.3% in FY2024 to 40.6% in FY2025) after that customer's key client was impacted by increased U.S. import tariffs. Gross profit declined from $4.5 million in 2024 to $2.9 million in 2025, while active customer count fell to 26 from 37 amid customer portfolio realignments. The company incurred a working capital deficit of $7.7 million, raising substantial doubt about its ability to continue as a going concern, though it secured a post-period $3.0 million note financing and an up to $50.0 million share purchase facility in March 2026.
- Consolidated revenue declined ~44% YoY to approximately $6.0 million in FY2025 from $10.8 million in FY2024, with gross profit decreasing to $2.9 million from $4.5 million.
- Customer concentration remained high with top five customers representing 74.0% of revenue in 2025 (down from 86.2% in 2024), while the largest single customer accounted for 40.6% of revenue in 2025 compared to 73.3% in 2024.
- Working capital deficit widened to approximately $7.7 million as of December 31, 2025 (from $6.0 million in 2024), resulting in a going-concern warning.
- ·SEC APIfinancials
6-K Financial Filing Analysis for KNOREX (2026-08-26)
On August 21, 2026, KNOREX Ltd. received a deficiency notice from NYSE Regulation regarding non-compliance with NYSE American continued listing standards under Sections 1003(a)(i) and 1003(a)(ii). The non-compliance stems from consecutive net losses over the last four fiscal years and a stockholders' deficit of $(6.5) million as of December 31, 2025, against minimum stockholders' equity requirements of $2.0 million to $4.0 million. The company plans to submit a compliance plan by September 20, 2026, seeking to regain compliance by February 21, 2028, during which its Class A ordinary shares will continue trading normally subject to NYSE acceptance and progress milestones.
- KNOREX received an NYSE American non-compliance notice on August 21, 2026, due to a reported stockholders' deficit of $(6.5) million as of December 31, 2025, and four consecutive years of net losses.
- The company must submit a compliance plan by September 20, 2026, to demonstrate how it will meet the equity threshold by February 21, 2028.
- Trading of Class A ordinary shares continues unaffected during the cure period, but failure to submit an acceptable plan or meet milestones will trigger delisting proceedings.
NextRoll
Recent Signals
No recent market signals documented for NextRoll in the current tracking window.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners KNOREX and NextRoll share across the market ecosystem.